Clinical Trials Logo
  1. Home
  2. Oligometastatic Disease
  3. NCT04141709

Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer — OLI-CR-P  

Oligometastatic Disease Clinical Trial

Official title:
Effektivität Und Toxizität Einer Perkutanen Hochdosierten Strahlentherapie Bei Patienten Mit Oligometastasen Eines Kastrationsresistenten Prostatakarzinoms

Clinical Trial Summary

The purpose of this randomized trial is to investigate the efficacy and toxicity of percutaneous high-dose radiotherapy in patients with oligometastases of hormone refractory prostate cancer. The effectiveness will be tested in comparison to an observation group, in which no further therapy is initially given. Treatment can be stereotactically hypofractionated or conventionally fractionated.

Clinical Trial Description

This is a monocentric, randomized, prospective Phase II intervention trial. Efficacy is measured as the rate in patients with PSA progression one year after randomization (defined as PSA nadir after randomization +2 ng/ml). There is a 2:1 randomization between intervention and observation group. Patients with PSA progression in the observation group are offered a new diagnosis. This should preferably correspond to the initial diagnosis. Therapy is performed for all patients in the intervention arm using high dose radiation therapy, either as conventional fractional irradiation with 2 Gy/fraction up to a total dose of 50 Gy or as hypofractional irradiation with a single dose of 10 Gy up to a total dose of 30 Gy. The decision as to which regimen the patient is to be treated according to is made by the treating physician, taking into account in particular the location of the volume to be irradiated in relation to the organs at risk and any previous irradiation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04141709
Study type Interventional
Source Technische Universität Dresden
Contact Tobias Hölscher, Dr.
Phone +493514582238
Email str.studien@uniklinikum-dresden.de
Status Recruiting
Phase N/A
Start date December 1, 2019
Completion date February 28, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06190782 - Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor Phase 3
Not yet recruiting NCT06373497 - Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography Early Phase 1
Recruiting NCT05377047 - Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer N/A
Recruiting NCT05223803 - TERPS Trial for de Novo Oligometastic Prostate Cancer Phase 2
Recruiting NCT04617457 - Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas Phase 2
Recruiting NCT04821765 - Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer Phase 2
Recruiting NCT05679427 - Ablative Radiosurgery vs Stereotactic RT in 5 Fractions With SIB for Oligometastatic Bone Lesions N/A
Recruiting NCT05277844 - Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC Phase 2
Active, not recruiting NCT05951127 - Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC N/A
Active, not recruiting NCT05101824 - Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease N/A
Not yet recruiting NCT06430411 - Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
Recruiting NCT04748042 - Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) Phase 2
Recruiting NCT06122480 - Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma N/A
Not yet recruiting NCT05784428 - Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression N/A
Completed NCT04593381 - Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer N/A
Terminated NCT01345539 - Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation Phase 2
Recruiting NCT05846646 - Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC Phase 2
Recruiting NCT04973007 - Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases Phase 4
Recruiting NCT06439888 - Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT05917431 - Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC Phase 2